This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Biondi A, Cimino G, Pieters R, Pui CH . Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24–33.
Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children’s Cancer Group. J Clin Oncol 1999; 17: 445–455.
Hilden JM, Dinndorf PA, Meerbaum SO, Sather H, Villaluna D, Heerema NA et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 2006; 108: 441–451.
Chessells JM, Harrison CJ, Watson SL, Vora AJ, Richards SM . Treatment of infants with lymphoblastic leukaemia: results of the UK Infant Protocols 1987-1999. Br J Haematol 2002; 117: 306–314.
Frankel LS, Ochs J, Shuster JJ, Dubowy R, Bowman WP, Hockenberry-Eaton M et al. Therapeutic trial for infant acute lymphoblastic leukemia: the Pediatric Oncology Group experience (POG 8493). J PediatrHematol Oncol 1997; 19: 35–42.
Pieters R, Schrappe M, De Lorenzo P, Hann I, De RG, Felice M et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007; 370: 240–250.
Chessells JM, Harrison CJ, Kempski H, Webb DK, Wheatley K, Hann IM et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002; 16: 776–784.
Heerema NA, Sather HN, Ge J, Arthur DC, Hilden JM, Trigg ME et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11)—a report of the Children’s Cancer Group. Leukemia 1999; 13: 679–686.
Salzer WL, Jones TL, Devidas M, Hilden JM, Winick N, Hunger S et al. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children’s Oncology Group P9407. Pediatric Blood Cancer 2012; 59: 834–839.
Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429–438.
von Bergh AR, van DE, van Wering ER, van Zutven LJ, Hainmann I, Lonnerholm G et al. High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes ChromosomesCancer 2006; 45: 731–739.
Heerema NA, Sather HN, Sensel MG, La MK, Hutchinson RJ, Nachman JB et al. Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia. Cancer 2002; 94: 1102–1110.
Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, Atlas SR et al. Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2012; 119: 1872–1881.
Stam RW, Schneider P, de Lorenzo P, Valsecchi MG, den Boer ML, Pieters R . Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2007; 110: 2774–2775.
Acknowledgements
This work was supported in part by grants from the NCI to the Children’s Oncology Group including U10 CA98543 (COG Chair's grant), U10 CA98413 (COG Statistics & Data Center) and U24 CA114766 (COG Specimen Banking). CLW and RH were additionally supported by a Leukemia and Lymphoma Specialized Center of Research Grant in Infant Leukemia (17 372). SPH is the Ergen Family Chair in Pediatric Cancer. The study was also partially supported by Leukaemia Lymphoma Research, UK (to CJH and AVM) and Associazione Italiana Ricerca sul Cancro: Investigator Grant Code 5017 (to MGV). The Interfant99 international study operating center is partially supported by Fondazione Tettamanti and Comitato ML Verga (to MGV and PDL).
AUTHOR CONTRIBUTIONS
CJH, AVM, RP and MGV designed the study. SPH as Chair of COG, ZED as Chair of the COG-P9407 trial and MD provided data from this trial. MGV and RP provided data from Interfant-99. NAH and AJC provided cytogenetic data from COG. RH and CLW provided FLT3 data. PDL, MGV and AVM carried out statistical analysis. CJH, AVM and SPH wrote the paper. All authors approved the final version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Rights and permissions
About this article
Cite this article
De Lorenzo, P., Moorman, A., Pieters, R. et al. Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. Leukemia 28, 428–430 (2014). https://doi.org/10.1038/leu.2013.280
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.280
This article is cited by
-
Cytogenetic Characteristics of Childhood Acute Lymphoblastic Leukemia: A Study of 1541 Chinese Patients Newly Diagnosed between 2001 and 2014
Current Medical Science (2022)
-
Acute Leukemia in Infants
Current Oncology Reports (2021)
-
Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study
Leukemia (2021)
-
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
Nature Genetics (2015)